Talk to the analystsTalk to us
Language: EN
Talk to the analysts

Research

Every report, free and in full. Released to all investors at the same moment.

  1. Fourth quarter 2026

  2. Ask this report

    Sirnaomics Update

    The RNAimmune money is in, and the FDA has answered in writing on STP705 (PDF, opens in a new tab)

  3. Third quarter 2026

  4. Ask this report

    Ainos Update

    A partner pays for VELDONA, and Ainos keeps the platform (PDF, opens in a new tab)

  5. Ask this report

    Ainos Update

    A front-end customer starts ordering, and the dataset passes a billion (PDF, opens in a new tab)

  6. Ask this report

    Ainos Update

    Three patents granted in Japan, and a dataset gathering pace (PDF, opens in a new tab)

  7. Ask this report

    Sirnaomics Initiation

    Every approved siRNA drug works in the liver. This one was injected into skin cancer (PDF, opens in a new tab)

  8. Ask this report

    Baladna Update

    The capital is raised, and the Algeria build is under way (PDF, opens in a new tab)

  9. Ask this report

    Zaptec Initiation

    Europe’s largest AC charging brand (PDF, opens in a new tab)

  10. Ask this report

    Spinneys Update

    The estate grew 17%; the recovery needs no capital (PDF, opens in a new tab)

  11. Ask this report

    Ainos Update

    613 million records, and a cost base that did not move: Ainos’s first half 2026 (PDF, opens in a new tab)

  12. Ask this report

    Luberef Update

    Record first-half earnings as base oil margins drive cash flow (PDF, opens in a new tab)

  13. Ask this report

    Baladna Initiation

    Priced as dairy, built as infrastructure: the quiet compounding of a sovereign food-security platform (PDF, opens in a new tab)

  14. Second quarter 2026

  15. Ask this report

    Ainos Update

    AI Nose starts reading the breath itself: a new emergency-medicine study at National Taiwan University (PDF, opens in a new tab)

  16. Ask this report

    Ainos Update

    AI Nose enters the emergency room: the first live hospital deployment (PDF, opens in a new tab)

  17. Ask this report

    Luberef Update

    Q1 confirms earnings resilience and Growth II progress (PDF, opens in a new tab)

  18. Ask this report

    Ainos Update

    AI Nose builds a broader operating footprint across semiconductors and healthcare (PDF, opens in a new tab)

  19. Ask this report

    Spinneys Update

    Q1 2026: demand quality holds (PDF, opens in a new tab)

  20. Ask this report

    Ainos Update

    AI Nose expands into hospital infrastructure: platform adoption gains a new vertical (PDF, opens in a new tab)

  21. Ask this report

    Luberef Initiation

    Luberef: a specialty base oils platform with clear execution markers and resilient cash generation (PDF, opens in a new tab)

  22. Ask this report

    Spinneys Update

    Core operations remain intact (PDF, opens in a new tab)

  23. Ask this report

    Ainos Update

    FY2025 and the 10-K add definition to the 2026 commercial setup (PDF, opens in a new tab)

  24. First quarter 2026

  25. Ask this report

    Ainos Update

    Ainos and ASE: deposit received; phase-one delivery targeted (Q2 2026) (PDF, opens in a new tab)

  26. Ask this report

    Ainos Update

    What we learned from the VELDONA FCGS interim readout (PDF, opens in a new tab)

  27. Ask this report

    Spinneys Update

    FY2025 execution supports continued growth (PDF, opens in a new tab)

  28. Ask this report

    Spinneys Initiation

    Spinneys: premium grocery leader in the UAE, scaling in Saudi Arabia, a clean execution test (PDF, opens in a new tab)

  29. Ask this report

    Ainos Update

    AI Nose expands into robotic sensing for inspection and safety monitoring (PDF, opens in a new tab)

  30. Ask this report

    Ainos Initiation

    Two engines, two timelines: AI Nose execution and VELDONA clinical gates (PDF, opens in a new tab)

Research, not investment advice. Every report carries its full disclosures. Research disclosures